Last-Chance access: experimental drug offered to mitochondrial disease patients
NCT ID NCT07159139
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This program gave patients with inherited mitochondrial diseases like Leigh syndrome continued access to the experimental drug vatiquinone after they finished a previous safety study. Only those who had already taken vatiquinone and could not join another trial were eligible. The program is no longer available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.